NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered Retatrutide from Xingruida XDR? Mail in a sample (US only) and let us test it.

Test my supply
+4 more ↓
78%
Finnrick rating
#195 of 419 Retatrutide vendors
25 of 32 classifiable tests passed
customers 4.7★ (11)
methodology · Purity focus
Finnrick analysis · Retatrutide

Xingruida XDR Retatrutide has a mixed record: solid purity runs are offset by major fill failures, including -47% and -52% underfills. The recent identity fail dented the trajectory, though the next test was clean.

methodology →
vendor intelligence report
Vendor Intelligence Report: Xingruida XDR

Corporate filings trace a dissolved UK namesake and a live Hong Kong layer without resolving the storefront’s controller. The report also maps shared-hosting overlap with Mammoth Biotech and a brand-keyword WhatsApp doorway network.

38 pages8 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Tirzepatide
$0.33
79%
24
2
Retatrutideselected
$0.99
78%
32
3
Ipamorelin
$0.90
73%
3
4
GHK-Cu
$0.08
71%
9
5
Melanotan II
$0.58
61%
2
6
PT-141
-
60%
3
7
Tesamorelin
$2.42
55%
10
8
BPC-157
$1.04
54%
8
9
TB-500
$1.74
43%
3
10
Cagrilintide
$3.38
-
0
12
Semaglutide
$2.14
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%20 Jun 2025: 58%24 Jul 2025: 61%4 Aug 2025: 64%21 Aug 2025: 64%1 Sep 2025: 61%4 Sep 2025: 64%4 Sep 2025: 66%10 Sep 2025: 68%18 Sep 2025: 70%30 Sep 2025: 72%5 Oct 2025: 74%29 Oct 2025: 75%4 Nov 2025: 76%14 Nov 2025: 78%17 Nov 2025: 78%17 Nov 2025: 75%23 Nov 2025: 76%25 Nov 2025: 77%25 Nov 2025: 78%25 Nov 2025: 79%15 Feb 2026: 81%26 Feb 2026: 81%13 Mar 2026: 82%8 May 2026: 79%25 May 2026: 80%5 Jun 2026: 81%30 Jul 2026: 81%9 Aug 2026: 82%12 Aug 2026: 83%12 Aug 2026: 80%20 Oct 2026: 77%30 Oct 2026: 78%15 Nov 2026: current 78%58%81%78%Jun 25Nov 26
Showing Retatrutide tests only
Peptide testing

Ordered Retatrutide from Xingruida XDR? Mail in a sample (US only) and let us test it.

Test my supply
Xingruida XDR Retatrutide test history
COA-backed lab tests
1-10 of 32

About Xingruida XDR test results from Finnrick

Xingruida XDR is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 9 peptides and 94 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Xingruida XDR peptides in this dataset are BPC-157 (8 tests), GHK-Cu (9 tests) and Ipamorelin (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 94 recent tests.

Corrections
No corrections.
Peptide testing

Ordered Retatrutide from Xingruida XDR? Mail in a sample (US only) and let us test it.

Test my supply